Want to see MAZE full AI Analyst Report?
Top Page
Maze Therapeutics, Inc.
(NASDAQ:MAZE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$28.00
▼(-5.34% Downside)
Action:Reiterated
Date:09/23/26
The score is primarily held down by weak financial performance driven by sizable losses and sustained cash burn, partially offset by a comparatively stronger balance sheet with low leverage. Technicals are mixed (above short-term averages but below the 200-day with negative MACD), and valuation remains pressured due to negative earnings and no dividend support.
Positive Factors
Low balance-sheet leverage
Equity of $453.1M and low debt relative to assets provide a meaningful capital base for continued development, while debt-to-equity of about 0.13 limits balance-sheet leverage. This cushion can preserve flexibility as Maze funds clinical programs.
Negative Factors
Sustained cash burn
Large negative operating and free cash flow show that Maze is consuming substantial cash to operate and develop its programs. Continued outflows may increase future funding needs, reduce financial flexibility, and make progress dependent on maintaining adequate capital resources.
Read all positive and negative factors
Positive Factors
Negative Factors
Low balance-sheet leverage
Equity of $453.1M and low debt relative to assets provide a meaningful capital base for continued development, while debt-to-equity of about 0.13 limits balance-sheet leverage. This cushion can preserve flexibility as Maze funds clinical programs.
Read all positive factors
Maze Therapeutics, Inc. (MAZE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.46B
Dividend YieldN/A
Average Volume (3M)728.58K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth700.00%
EPS Growth-50.45%
CountryUS
Employees141
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.74
Shares Outstanding55,549,168
10 Day Avg. Volume831,710
30 Day Avg. Volume728,580
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue70.49
Enterprise Value/Gross Profit73.98
Enterprise Value/Ebitda-10.85
Forecast
1Y Price Target
$61.43Price Target Upside107.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.78
Revenue Forecast (FY)$20.00M
Maze Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhi...
Maze Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.00M | 0.00 | 167.50M | 0.00 | 0.00 |
| Gross Profit | 19.06M | -2.40M | 167.50M | 0.00 | 0.00 |
| EBITDA | -129.89M | -128.72M | 56.70M | -96.33M | -111.12M |
| Net Income | -133.59M | -131.12M | 52.23M | -100.42M | -114.94M |
Balance Sheet | |||||
| Total Assets | 531.63M | 397.13M | 240.54M | 71.50M | 149.96M |
| Cash, Cash Equivalents and Short-Term Investments | 411.09M | 341.92M | 196.81M | 29.16M | 99.92M |
| Total Debt | 60.42M | 23.31M | 26.63M | 49.62M | 32.05M |
| Total Liabilities | 78.50M | 42.16M | 43.64M | 61.45M | 48.51M |
| Stockholders Equity | 453.12M | 354.97M | 196.90M | 10.05M | 101.44M |
Cash Flow | |||||
| Free Cash Flow | -106.84M | -112.73M | 74.81M | -87.27M | -101.17M |
| Operating Cash Flow | -106.54M | -111.94M | 75.95M | -86.83M | -99.20M |
| Investing Cash Flow | -292.50M | -170.96M | -1.15M | -441.00K | -3.17M |
| Financing Cash Flow | 337.14M | 275.34M | 92.85M | 16.39M | 1.73M |
Maze Therapeutics, Inc. Technical Analysis
Negative
29.58
Price Trends
26.87
Negative
27.00
Negative
32.71
Negative
Market Momentum
-0.05
Negative
47.14
Neutral
40.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MAZE, the sentiment is Negative. The current price of 29.58 is above the 20-day moving average (MA) of 25.68, above the 50-day MA of 26.87, and below the 200-day MA of 32.71, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.14 is Neutral, neither overbought nor oversold. The STOCH value of 40.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MAZE.
Maze Therapeutics, Inc. Risk Analysis
Maze Therapeutics, Inc. disclosed 84 risk factors in its most recent earnings report. Maze Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
Maze Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $1.64B | -3.75 | -57.79% | ― | 12.58% | 28.42% | |
56 Neutral | $2.29B | -3.80 | -50.41% | ― | -15.08% | 41.98% | |
55 Neutral | $772.39M | -2.26 | -60.21% | ― | -51.54% | 7.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.74B | -13.20 | -108.80% | ― | ― | ― | |
47 Neutral | $1.25B | -0.16 | -82.56% | ― | ― | -850.33% | |
46 Neutral | $1.46B | -9.45 | -34.94% | ― | 700.00% | -50.45% |
* Healthcare Sector Average
MAZE
Maze Therapeutics, Inc.
25.88
-2.88
-10.01%
NTLA
Intellia Therapeutics
12.60
-12.86
-50.51%
DMRA
Damora Therapeutics
20.56
5.81
39.39%
RXRX
Recursion Pharmaceuticals
3.95
-1.96
-33.16%
DNA
Ginkgo Bioworks Holdings
11.34
-3.90
-25.59%
GENB
Generate Biomedicines, Inc.
13.99
1.34
10.59%
Maze Therapeutics, Inc. Corporate Events
Business Operations and StrategyExecutive/Board Changes
Maze Therapeutics Strengthens Board with New Director Appointments
Positive
Aug 17, 2026
On August 13, 2026, Maze Therapeutics appointed Paula A. Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its board of directors, expanding governance with deep clinical, academic and biopharmaceutical leadership.
Johnson joins as...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.